HSD17B14

Across TCGA pan-cancer cohorts, HSD17B14 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of HSD17B14’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HSD17B14 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types HSD17B14 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where HSD17B14 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HSD17B14 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	−1.021	<.001	11	view →
LSCC	Male	All	−0.305	<.001	6	view →
LUAD	Male	All	−0.418	<.001	4	view →
PDAC	Male	III,IV	−0.400	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

HSD17B14–CCRCC

Open the CCRCC breakdown →